It’s Time for CAR T

Every eligible patient should get the opportunity for cure with CAR T-cell therapy.

By 2030 we aim to double the proportion of eligible  patients treated with CAR T-cell therapy.

On the site you can learn more about the CAR T Vision coalition and goals,
and review or download the new roadmap report.

Report executive summary

CAR T-cell therapy is a potentially curative treatment for patients with blood cancer. However, as this report will outline in more detail, currently too many eligible patients are missing out on CAR T-cell therapy and the outcomes it can offer.

Call to action

We call on patient and caregiver organizations, HCPs, payors, HTA bodies, regulators, policymakers, legislators, and industry, to consider how you can contribute to efforts to ensure more eligible patients get access to CAR T-cell therapy in the next five years.

CAR T Vision Steering Committee

Members of the multidisciplinary global Steering Committee include leading hematologists, patient advocacy and clinical society leaders, technical experts and health economists, with experience from across Europe and North America.

Miguel-Angel Perales, MD (Co-Chair) 

Past-President (2023-24), American Society for Transplantation and Cellular Therapy (ASTCT) 

Anna Sureda, MD, PhD (Co-Chair)

Clinical Hematologist, Professor and Cell Therapy Researcher

Jacqueline Barry

Executive Director, Cell and Gene Therapy Catapult (CGT Catapult)

Yelak Biru

Immediate Past-President and Chief Executive Officer, International Myeloma Foundation (IMF)

John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci

Barts Cancer Institute, London, and Past President of the European Hematology Association (EHA)

Meghan Gutierrez

Chief Executive Officer, Lymphoma Research Foundation (LRF)

Michael Hudecek, PhD

Professor in Cellular Immunotherapy, Universitätsklinikum Würzburg, Germany; Project Coordinator, T2EVOLVE IMI Consortium

Tim Hunt

Chief Executive Officer, Alliance for Regenerative Medicine (ARM)

Meagan O’Neill, MS

Executive Director, Association of Cancer Care Centers (ACCC)

David Schmahl 

Chief Executive Officer, Foundation for the Accreditation of Cellular Therapy (FACT)  

Brian O’Rourke, BSP, Pharm.D., OMM

Independent Healthcare Advisor

Lorna Warwick

Chief Executive Officer, Lymphoma Coalition

Jason Westin, MD, MS, FACP, FASCO

Medical Oncologist, Professor and Cell Therapy Researcher

Endorsements

In developing the CAR T Vision and report, the Steering Committee consulted with experts and advocates to understand how the Vision can support their work and advocacy. As a result, several organizations have endorsed the CAR T Vision.

Introduction and overview

Vision for improving patient access to CAR T-cell therapy

We believe every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, we aim to double the proportion of eligible patients treated with CAR T-cell therapy.

An overview of CAR T-cell therapy

CAR T-cell therapy involves removing a person’s T-cells through a process called leukapheresis, where blood is drawn from a vein and T-cells are separated from the blood.

Patient access to CAR T-cell therapy

Despite the life-saving potential of CAR T-cell therapies, a large proportion of eligible patients struggle to access them.

The opportunities for change

To inform the focus and goals of the CAR T Vision, the Steering Committee discussed the current challenges to access across the patient pathway, and identified three key sets of challenges which the CAR T Vision must seek to address.

Case studies

The purpose of these case studies is to provide short, digestible examples of implementable solutions to address common challenges to CAR T-cell therapy.

See all case studies

CAR T Vision

Every eligible patient should get the opportunity for cure with CAR T-cell therapy.

By 2030 we aim to double the proportion of eligible patients treated with CAR T-cell therapy.

Download report